<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7288254\results\search\disease\results.xml">
  <result pre="understanding of virus-induced cell death leads to highly immunogenic oncolytic" exact="influenza" post="viruses KabiljoJulijan1http://orcid.org/0000-0003-4771-1398LaengleJohannes12http://orcid.org/0000-0001-8529-1166BergmannMichaelmichael.bergmann@meduniwien.ac.at12[1], 0000 0000 9259 8492grid.22937.3dDivision of General Surgery,"/>
  <result pre="http://creativecommons.org/licenses/by/4.0/. Abstract Oncolytic viruses constitute an emerging strategy in immunomodulatory" exact="cancer" post="treatment. The first oncolytic virus, Talimogene laherparepvec (T-VEC), based"/>
  <result pre="treatment. The first oncolytic virus, Talimogene laherparepvec (T-VEC), based on" exact="herpes simplex" post="virus 1 (HSV-1), was approved by the Food and"/>
  <result pre="infection but never leads to a chronic disease. While oncolytic" exact="influenza" post="A viruses are in preclinical development, they have not"/>
  <result pre="Recent insights into different types of cell death caused by" exact="influenza" post="A virus infection illuminate novel possibilities of enhancing its"/>
  <result pre="of enhancing its therapeutic effect. Genetic engineering and experience in" exact="influenza" post="A virus vaccine development allow safe application of the"/>
  <result pre="we give a summary of efforts undertaken to develop oncolytic" exact="influenza" post="A viruses. We discuss strategies for targeting viral replication"/>
  <result pre="furthermore describe which modes of cell death are induced by" exact="influenza" post="A virus infection and how these insights may be"/>
  <result pre="infection and how these insights may be utilized to optimize" exact="influenza" post="A virus-based oncolytic virus design. Subject terms Tumour immunology"/>
  <result pre="terms Tumour immunology Tumour virus infections Cancer immunotherapy Facts Oncolytic" exact="influenza" post="A virus displays selective replication in tumor cells. Influenza"/>
  <result pre="be targeted to tumors and armed with cytokines. Growth optimized" exact="influenza" post="A virus for a phase I application can be"/>
  <result pre="virus for a phase I application can be generated. Oncolytic" exact="influenza" post="A virus prototypes have been tested in humans as"/>
  <result pre="of a complete tumor remission in the context of an" exact="influenza" post="A infection dates back to 19043. Preclinical models solidified"/>
  <result pre="19043. Preclinical models solidified the assertion of oncolytic effects of" exact="influenza" post="A viruses4,5. However, the lack of understanding of virus"/>
  <result pre="the clinical development of a variety of oncolytic viruses, including" exact="herpes simplex" post="virus (HSV)6, reovirus7, vaccinia virus (VV)8, vesicular stomatitis virus"/>
  <result pre="variety of oncolytic viruses, including herpes simplex virus (HSV)6, reovirus7," exact="vaccinia virus" post="(VV)8, vesicular stomatitis virus (VSV)9, adenovirus10, newcastle disease virus"/>
  <result pre="including herpes simplex virus (HSV)6, reovirus7, vaccinia virus (VV)8, vesicular" exact="stomatitis" post="virus (VSV)9, adenovirus10, newcastle disease virus (NDV)11, measles virus"/>
  <result pre="(VV)8, vesicular stomatitis virus (VSV)9, adenovirus10, newcastle disease virus (NDV)11," exact="measles" post="virus (MeV)12 and picornaviridae13. This renewed interest in oncolytic"/>
  <result pre="interest in the field of virotherapy. With respect to oncolytic" exact="influenza" post="A viruses, only preclinical studies have been accomplished yet,"/>
  <result pre="review we summarize major milestones in the development of oncolytic" exact="influenza" post="A viruses. We delineate in which manner targeted replication"/>
  <result pre="A viruses. We delineate in which manner targeted replication in" exact="cancer" post="cells was achieved. Furthermore, we discuss strategies to arm"/>
  <result pre="cancer cells was achieved. Furthermore, we discuss strategies to arm" exact="influenza" post="A viruses with immuno-stimulatory transgenes. Finally, we discuss which"/>
  <result pre="immuno-stimulatory transgenes. Finally, we discuss which types of cell death" exact="influenza" post="A virus-infected cancer cells succumb to and their implications"/>
  <result pre="we discuss which types of cell death influenza A virus-infected" exact="cancer" post="cells succumb to and their implications for future design"/>
  <result pre="enhance its immunogenicity or stimulate targeted anti-cancer mechanisms. Utilizing an" exact="influenza" post="A virus as an oncolytic agent has several advantages."/>
  <result pre="A virus as an oncolytic agent has several advantages. The" exact="influenza" post="virus is a small virus of the Orthomyxoviridae family,"/>
  <result pre="commonly known for causing the flu28. It comprises 4 genera," exact="influenza" post="A, B, C, and D viruses, type A being"/>
  <result pre="type A being the most extensively studied one28,29. While the" exact="influenza" post="virus can induce strong immunogenic reactions and intense pathology"/>
  <result pre="ideal vector for oncolytic therapy. Oncolytic virus development focused on" exact="influenza" post="A virus. This virus subtype contains 8 separate RNA"/>
  <result pre="that has previously been established for the production of seasonal" exact="influenza" post="vaccinations reduces the amount of novel biotechnological engineering and"/>
  <result pre="in the field of oncology33. Fig. 1 Components of the" exact="influenza" post="A virus. Schematic representation of all components of the"/>
  <result pre="influenza A virus. Schematic representation of all components of the" exact="influenza" post="A virus virion. The interplay of influenza virus and"/>
  <result pre="components of the influenza A virus virion. The interplay of" exact="influenza" post="virus and cell death The rational development of a"/>
  <result pre="with the pro-apoptotic scribbled planar cell polarity protein (scribble)42. However," exact="influenza" post="A viruses have a two-sided relationship to apoptosis37. There"/>
  <result pre="two-sided relationship to apoptosis37. There is evidence, that growth of" exact="influenza" post="viruses is dependent on apoptosis43. Specifically, caspase 3 appears"/>
  <result pre="3 appears important for viral replication44. In this line, the" exact="influenza" post="A virus can actively induce apoptosis. Apoptotic signaling may"/>
  <result pre="viral protein PB1-F245. A further major inducer of apoptosis during" exact="influenza" post="A virus infections is the viral nucleoprotein (NP), interacting"/>
  <result pre="transforming growth factor beta (TGF-β)49. There are multiple theories, why" exact="influenza" post="A virus may actively induce apoptosis. Overall, there seems"/>
  <result pre="tightly controlled by the virus. Upon overexpression of anti-apoptotic molecules" exact="influenza" post="A virus titers are reduced due to viral RNA-protein"/>
  <result pre="reinforced by the observation, that the anti-mycotic amphotericin B enhances" exact="influenza" post="virus growth52. Amphotericin B stabilizes pores within cellular membranes."/>
  <result pre="from the nucleus. Fig. 2 A proposed model of how" exact="influenza" post="A virus controls apoptosis in 2 phases. a In"/>
  <result pre="in 2 phases. a In the early phase of an" exact="influenza" post="virus infection, the virus benefits from reduced apoptosis, in"/>
  <result pre="NF-κB induced TNFα release. b In the late phase of" exact="influenza" post="virus infection, the pro apoptotic viral protein PB1-F2 and"/>
  <result pre="out of the cell, resulting in immunogenic reactions55,56. In conclusion," exact="influenza" post="A virus induces an apoptotic cell death through a"/>
  <result pre="a virus that initiates potent anti-cancer-immune responses without causing an" exact="infectious disease," post="it is necessary to target them to cancer cells."/>
  <result pre="an infectious disease, it is necessary to target them to" exact="cancer" post="cells. Mammalian cells react to viral infections by secreting"/>
  <result pre="to circumvent these immunogenic effects. It was shown, that the" exact="influenza" post="A virus lacking NS1 (delNS1) generated by Egorov et"/>
  <result pre="appeared to be an attractive strategy for targeting growth of" exact="influenza" post="A viruses to malignant tissue. We were able to"/>
  <result pre="deletions of various lengths within the NS1 gene of an" exact="influenza" post="A/Puerto Rico/8/34 (PR8) based H1N1 virus yielded potent anti-cancer"/>
  <result pre="xenografts61. Another mechanism through which NS1 counteracts cellular responses to" exact="influenza" post="A virus infection is the inhibition of the double-stranded"/>
  <result pre="the double-stranded RNA sensor PKR36,62,63. We demonstrated that NS1 deleted" exact="influenza" post="A virus was lethal to PKR knockout mice but"/>
  <result pre="mice but was not lethal in wild-type mice36. Oncogenic rat" exact="sarcoma" post="(RAS) gene mutation, present in approximately a third of"/>
  <result pre="(RAS) gene mutation, present in approximately a third of all" exact="cancer" post="subtypes, results in PKR inhibition64. We showed that NS1"/>
  <result pre="PKR inhibition64. We showed that NS1 deletion targets a PR8" exact="influenza" post="virus towards RAS mutated tumors in a PKR dependent"/>
  <result pre="transfected with oncogenic RAS65. There are also developments of oncolytic" exact="influenza" post="A viruses, which are based on attenuation markers other"/>
  <result pre="the NS1 deletion. One preclinical study in murine non-small cell" exact="lung cancer" post="(NSCLC) xenografts showed efficacy and safety of wild-type NS1,"/>
  <result pre="NS1 deletion. One preclinical study in murine non-small cell lung" exact="cancer" post="(NSCLC) xenografts showed efficacy and safety of wild-type NS1,"/>
  <result pre="PR8 H1N1 virus66. Another study screened a variety of wild-type" exact="influenza" post="A viruses for their infectivity in pancreatic carcinoma cell"/>
  <result pre="system Apart from the conditionally replicating phenotype in malignant cells" exact="influenza" post="A viruses with NS1 deletions are associated with a"/>
  <result pre="interferon regulatory factor 3 (IRF3) and NF-κB48,68. Since NS1 deleted" exact="influenza" post="A viruses are capable of inducing strong PKR pathway"/>
  <result pre="as a DAMP, causing enhanced immunogenicity of apoptotic bodies after" exact="influenza" post="A virus infection in PKR sensitive cancers70. Fig. 3"/>
  <result pre="infection in PKR sensitive cancers70. Fig. 3 Functions of the" exact="influenza" post="A virus NS1 protein and generation of an armed"/>
  <result pre="A virus NS1 protein and generation of an armed oncolytic" exact="influenza" post="A virus. a Schematic representation of the NS1 protein."/>
  <result pre="to are indicated42,48,62,63,68,72,75. b Example of genetic modifications in an" exact="influenza" post="virus designed to be used as oncolytic agent94. Modifications"/>
  <result pre="peptide, 2A FMDV 2A cleavage site of the foot and" exact="mouth disease" post="virus. A transcriptional profiling confirmed that a delNS1 virus"/>
  <result pre="&quot;panhandle�?, which holds the single stranded RNA segments of the" exact="influenza" post="A virus genome in a circular conformation78–81. The immunogenic"/>
  <result pre="cell and B cell responses, protecting mice and ferrets against" exact="influenza" post="A virus challenge31,82. Importantly, the virus did not cause"/>
  <result pre="B cells, monocytes and natural killer (NK) cells against various" exact="cancer" post="cell lines87. These cytotoxic effects might contribute to the"/>
  <result pre="to the viruses’ therapeutic effect in the tumor microenvironment. Targeting" exact="influenza" post="viruses to tumor cells by viral entry Influenza A"/>
  <result pre="the tissue is substantial for host restriction. It restricts the" exact="influenza" post="A virus infection to the lung, the enteric system"/>
  <result pre="some viral isolates to the brain. We discovered that various" exact="colon cancer" post="cell lines express trypsin and allow oncolytic influenza A"/>
  <result pre="viral isolates to the brain. We discovered that various colon" exact="cancer" post="cell lines express trypsin and allow oncolytic influenza A"/>
  <result pre="various colon cancer cell lines express trypsin and allow oncolytic" exact="influenza" post="A virus growth in the absence of exogenous protease73."/>
  <result pre="in the absence of exogenous protease73. To further target the" exact="influenza" post="A virus to tumor tissue we generated a virus"/>
  <result pre="with an elastase cleavage site has been shown to attenuate" exact="influenza" post="A virus replication in swine and mice88–90. We therefore"/>
  <result pre="trypsin cleavage site within the partially NS1 deleted (116AA) PR8" exact="influenza" post="virus to elastase. Elastase-dependent viruses yielded a potent therapeutic"/>
  <result pre="human population, including the H7 or H9 subtypes. Arming oncolytic" exact="influenza" post="viruses to enhance immunogenicity Many clinical and preclinical studies"/>
  <result pre="preclinical studies have shown effectiveness of &quot;non-armed�? oncolytic viruses in" exact="cancer" post="treatment. Still, their immuno-stimulatory properties do not always result"/>
  <result pre="cytokines like interleukin-2 (IL-2), interleukin-15 (IL-15) or GM-CSF91. Within the" exact="influenza" post="A virus background we were able to establish potent"/>
  <result pre="maximum transgene loading capacity has not yet been tested in" exact="influenza" post="viruses. We demonstrated superior therapeutic efficacy and enhancement of"/>
  <result pre="cell activation and proliferation when the partially NS1 deleted (116)" exact="influenza" post="virus was armed with IL-1594 (Fig. 3b) in murine"/>
  <result pre="al. were able to show anti-cancer activity of an NS1-deleted" exact="influenza" post="A virus armed with GM-CSF in a human Hep-G2"/>
  <result pre="influenza A virus armed with GM-CSF in a human Hep-G2" exact="liver cancer" post="cell line xenograft model95. Hamilton et al. expressed a"/>
  <result pre="A virus armed with GM-CSF in a human Hep-G2 liver" exact="cancer" post="cell line xenograft model95. Hamilton et al. expressed a"/>
  <result pre="checkpoint inhibiting antibody from two different RNA fragments of the" exact="influenza" post="A virus genome in order to enhance its anti-cancer"/>
  <result pre="model96. In order to elicit specific immunological memory against known" exact="cancer" post="epitopes, Efferson et al. established a combined strategy of"/>
  <result pre="epitopes, Efferson et al. established a combined strategy of oncolytic" exact="influenza" post="A viruses armed with a vaccination peptide against the"/>
  <result pre="therapeutic outcomes in preclinical models have been postulated for oncolytic" exact="influenza" post="A viruses. Safety aspects of oncolytic influenza viruses Influenza"/>
  <result pre="postulated for oncolytic influenza A viruses. Safety aspects of oncolytic" exact="influenza" post="viruses Influenza viruses remain a major health concern as"/>
  <result pre="tested for its stable attenuation. The existence of licensed live" exact="influenza" post="A virus vaccines clearly indicates, that the genetic stability"/>
  <result pre="vaccines clearly indicates, that the genetic stability of attenuated live" exact="influenza" post="viruses is feasible. We could demonstrate that delNS1 viruses,"/>
  <result pre="reassortment of the chimeric segment with wild-type segments of other" exact="influenza" post="virus subtypes might lead to an unexpected pathogenic phenotype."/>
  <result pre="the background of various subtypes. Fig. 4 Reassortment of oncolytic" exact="influenza" post="A viruses and wild-type influenza A viruses. Examples of"/>
  <result pre="Fig. 4 Reassortment of oncolytic influenza A viruses and wild-type" exact="influenza" post="A viruses. Examples of reassortment of an armed oncolytic"/>
  <result pre="influenza A viruses. Examples of reassortment of an armed oncolytic" exact="influenza" post="virus attenuated by NS1 truncation during co-infection with wild-type"/>
  <result pre="influenza virus attenuated by NS1 truncation during co-infection with wild-type" exact="influenza" post="virus. a represents transgene expression from the NS1 reading"/>
  <result pre="virus. NS1 nonstructural 1 protein. Enhancing oncolytic activity of the" exact="influenza" post="A virus by optimizing immunogenic cell death – potential"/>
  <result pre="such as interleukin-24 (IL-24). We have shown that IL-24 sensitizes" exact="cancer" post="cells to apoptosis within the background of an influenza"/>
  <result pre="sensitizes cancer cells to apoptosis within the background of an" exact="influenza" post="A virus infection98. Importantly the apoptotic effect of IL-24"/>
  <result pre="achieved by IL-24 to the tumor microenvironment, as the attenuated" exact="influenza" post="virus used in this experiment cannot replicate otherwise. However,"/>
  <result pre="virus used in this experiment cannot replicate otherwise. However, an" exact="influenza" post="virus armed with IL-24 might be difficult to translate"/>
  <result pre="to passive release of a large variety of DAMPs and" exact="cancer" post="neo-antigen101. A recent report implicates necroptosis signaling through RIPK3"/>
  <result pre="protein 2 (cIAP2) protein has been shown to protect against" exact="influenza" post="A virus-induced necroptosis104. Necroptosis but also necrosis might be"/>
  <result pre="necroptosis104. Necroptosis but also necrosis might be induced by specific" exact="influenza" post="subtypes. Examples are the avian H5N1 and a reconstructed"/>
  <result pre="virus strains to cause necroptosis, specifically describing seasonal NC/99 H1N1" exact="influenza" post="A viruses as inducers and pandemic Cal/09 as inhibitors"/>
  <result pre="cell fate in this experiment. These results indicate that choosing" exact="influenza" post="A virus vectors according to their capability to initiate"/>
  <result pre="is a promising strategy for future oncolytic virus design. The" exact="influenza" post="A virus NS1 protein can directly cause necroptosis through"/>
  <result pre="been due to the lack of RIPK3 expression in the" exact="cancer" post="cell lines examined. It is well established, that RIPK3"/>
  <result pre="contribute to positive outcomes at least as much as necroptotic" exact="cancer" post="cells102. Therefore, the potential of candidate oncolytic viruses to"/>
  <result pre="of regulating immunogenicity in viral infections is oxeiptosis113. Viruses like" exact="influenza" post="A virus generate radical oxidative species (ROS). Cells can"/>
  <result pre="like necroptosis. PGAM5 knockout mice were shown to react to" exact="influenza" post="A virus infection with enhanced necrotic histology and rapid"/>
  <result pre="promising strategy to enhance oncolytic virotherapy. Further effects of oncolytic" exact="influenza" post="A viruses on the cancer-immune microenvironment shown in murine"/>
  <result pre="polarization towards immuno-stimulatory M1 phenotypes66,114. Recent evidence suggests NS1 deleted" exact="influenza" post="virus to exhibit enhanced growth when combined with an"/>
  <result pre="mechanisms like antibody-dependent, cell-mediated cytotoxicity (ADCC), which is reduced in" exact="breast cancer" post="patients118,119. The clinically approved oncolytic virus T-VEC is experimentally"/>
  <result pre="like antibody-dependent, cell-mediated cytotoxicity (ADCC), which is reduced in breast" exact="cancer" post="patients118,119. The clinically approved oncolytic virus T-VEC is experimentally"/>
  <result pre="checkpoint blockade26,121. Similar methods may prove to be successful in" exact="influenza" post="virus-based oncolytic virotherapy. Conclusion and outlook Influenza viruses attenuated"/>
  <result pre="a cofounder of Vacthera, a company seeking to develop oncolytic" exact="influenza" post="viruses. M.B. and J.L. received an investigator-sponsored research grant"/>
  <result pre="received consultant fees from Bristol-Myers-Squibb. References References 1.BlumingAZZieglerJLRegression of Burkitt’s" exact="lymphoma" post="in association with measles infectionLancet (Lond., Engl.)19712105106 2.TaqiAMAbdurrahmanMBYakubuAMFlemingAFRegression of"/>
  <result pre="Bristol-Myers-Squibb. References References 1.BlumingAZZieglerJLRegression of Burkitt’s lymphoma in association with" exact="measles" post="infectionLancet (Lond., Engl.)19712105106 2.TaqiAMAbdurrahmanMBYakubuAMFlemingAFRegression of Hodgkin’s disease after measlesLancet"/>
  <result pre="4.LindenmannJKleinPAViral oncolysis: increased immunogenicity of host cell antigen associated with" exact="influenza" post="virusJ. Exp. Med1967126931084290961 5.OnoSHattoriONagaiYNagataIOncolytic effect of influenza virus upon"/>
  <result pre="antigen associated with influenza virusJ. Exp. Med1967126931084290961 5.OnoSHattoriONagaiYNagataIOncolytic effect of" exact="influenza" post="virus upon Ehrlich carcinoma and Yoshida ascites hepatomaGan19554651251413262476 6.HarringtonKJet"/>
  <result pre="hepatomaGan19554651251413262476 6.HarringtonKJet al.Clinical development of talimogene laherparepvec (T-VEC): a modified" exact="herpes simplex" post="virus type-1-derived oncolytic immunotherapyExpert Rev. Anticancer Ther.2015151389140326558498 7.SamsonAet al.Intravenous"/>
  <result pre="immunotherapeutic vaccinia JX-594 in liver cancerNat. Med.20131932933623396206 9.MuikAet al.Semireplication-competent vesicular" exact="stomatitis" post="virus as a novel platform for oncolytic virotherapyJ. Mol."/>
  <result pre="specific immunization with Newcastle disease virus modified tumor cells in" exact="colorectal cancer" post="patients following resection of liver metastases: results of a"/>
  <result pre="immunization with Newcastle disease virus modified tumor cells in colorectal" exact="cancer" post="patients following resection of liver metastases: results of a"/>
  <result pre="prospective randomized trialCancer Immunol. Immunother.200958616918488223 12.MsaouelPet al.Clinical trials with oncolytic" exact="measles" post="virus: current status and future prospectsCurr. Cancer Drug Targets20181817718728228086"/>
  <result pre="18.BarlesiFet al.Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell" exact="lung cancer" post="(JAVELIN Lung 200): an open-label, randomised, phase 3 studyLancet"/>
  <result pre="al.Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung" exact="cancer" post="(JAVELIN Lung 200): an open-label, randomised, phase 3 studyLancet"/>
  <result pre="22.RittmeyerAet al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell" exact="lung cancer" post="(OAK): a phase 3, open-label, multicentre randomised controlled trialLancet"/>
  <result pre="al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung" exact="cancer" post="(OAK): a phase 3, open-label, multicentre randomised controlled trialLancet"/>
  <result pre="Sci.20201171119 LP112831888983 25.EngelandCEet al.CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic" exact="measles" post="virus therapyMol. Ther.2014221949195925156126 26.PuzanovIet al.Talimogene laherparepvec in combination with"/>
  <result pre="for the detection of immunogenic cell deathOncoimmunology20143e95569125941621 28.BouvierNMPalesePThe biology of" exact="influenza" post="virusesVaccine200826Suppl 4D49D5319230160 29.SuSFuXLiGKerlinFVeitMNovel influenza D virus: epidemiology, pathology, evolution"/>
  <result pre="immunogenic cell deathOncoimmunology20143e95569125941621 28.BouvierNMPalesePThe biology of influenza virusesVaccine200826Suppl 4D49D5319230160 29.SuSFuXLiGKerlinFVeitMNovel" exact="influenza" post="D virus: epidemiology, pathology, evolution and biological characteristicsVirulence201781580159128812422 30.BardsleySAAn"/>
  <result pre="vaccine approachProc. Natl Acad. Sci. U. S. A.2000974309431410725408 32.EgorovAet al.Transfectant" exact="influenza" post="A viruses with long deletions in the NS1 protein"/>
  <result pre="Dis.20189100230254192 35.ZhangJMiaoJHouJLuCMitochondrial antiviral signaling adaptor mediated apoptosis in H3N2 swine" exact="influenza" post="virus infection is inhibited by viral protein NS1 in"/>
  <result pre="Virol.2000746203 LP620610846107 37.LudwigSPleschkaSPlanzOWolffTRinging the alarm bells: signalling and apoptosis in" exact="influenza" post="virus infected cellsCell. Microbiol.2006837538616469051 38.TakizawaTet al.Induction of programmed cell"/>
  <result pre="cellsCell. Microbiol.2006837538616469051 38.TakizawaTet al.Induction of programmed cell death (apoptosis) by" exact="influenza" post="virus infection in tissue culture cellsJ. Gen. Virol.199374Pt 11234723557504071"/>
  <result pre="cellsJ. Gen. Virol.199374Pt 11234723557504071 39.GrahamACHilmerKMZickovichJMObarJJInflammatory response of mast cells during" exact="influenza" post="A virus infection is mediated by active infection and"/>
  <result pre="involvement of double-stranded RNA-activated protein kinase in cell death by" exact="influenza" post="virus infectionJ. Virol.199670812881328892939 41.BalachandranSet al.Alpha/beta interferons potentiate virus-induced apoptosis"/>
  <result pre="signaling pathwayJ. Virol.2000741513152310627563 42.LiuHet al.The ESEV PDZ-binding motif of the" exact="avian influenza" post="A virus NS1 protein protects infected cells from apoptosis"/>
  <result pre="pathwayJ. Virol.2000741513152310627563 42.LiuHet al.The ESEV PDZ-binding motif of the avian" exact="influenza" post="A virus NS1 protein protects infected cells from apoptosis"/>
  <result pre="cells from apoptosis by directly targeting ScribbleJ. Virol.201084111641117420702615 43.OlsenCWKehrenJCDybdahl-SissokoNRHinshawVSbcl-2 alters" exact="influenza" post="virus yield, spread, and hemagglutinin glycosylationJ. Virol.1996706636668523590 44.WurzerWJet al.Caspase"/>
  <result pre="glycosylationJ. Virol.1996706636668523590 44.WurzerWJet al.Caspase 3 activation is essential for efficient" exact="influenza" post="virus propagationEMBO J.2003222717272812773387 45.ChenWet al.A novel influenza A virus"/>
  <result pre="essential for efficient influenza virus propagationEMBO J.2003222717272812773387 45.ChenWet al.A novel" exact="influenza" post="A virus mitochondrial protein that induces cell deathNat. Med.200171306131211726970"/>
  <result pre="factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient" exact="influenza" post="virus propagationJ. Biol. Chem.2004279309313093715143063 48.WangXet al.Influenza A virus NS1"/>
  <result pre="factor betaJ. Virol.199670862486298970987 50.HinshawVSOlsenCWDybdahl-SissokoNEvansDApoptosis: a mechanism of cell killing by" exact="influenza" post="A and B virusesJ. Virol.199468366736738189504 51.FaleiroLLazebnikYCaspases disrupt the nuclear-cytoplasmic"/>
  <result pre="the nuclear-cytoplasmic barrierJ. Cell Biol.200015195195911085998 52.RoethlEet al.Antimycotic-antibiotic amphotericin B promotes" exact="influenza" post="virus replication in cell cultureJ. Virol.201185111391114521849438 53.YuHet al.Overcoming endosomal"/>
  <result pre="L. et al. Progesterone receptor attenuates STAT1-mediated IFN signaling in" exact="breast cancer." post="J. Immunol.10.4049/jimmunol.1801152 (2019) 61.MusterTet al.Interferon resistance promotes oncolysis by"/>
  <result pre="cancer. J. Immunol.10.4049/jimmunol.1801152 (2019) 61.MusterTet al.Interferon resistance promotes oncolysis by" exact="influenza" post="virus NS1-deletion mutantsInt. J. Cancer2004110152115054864 62.MinJ-YLiSSenGCKrugRMA site on the"/>
  <result pre="influenza virus NS1-deletion mutantsInt. J. Cancer2004110152115054864 62.MinJ-YLiSSenGCKrugRMA site on the" exact="influenza" post="A virus NS1 protein mediates both inhibition of PKR"/>
  <result pre="PKR activation and temporal regulation of viral RNA synthesisVirology200736323624317320139 63.HatadaESaitoSFukudaRMutant" exact="influenza" post="viruses with a defective NS1 protein cannot block the"/>
  <result pre="factor 2 alpha-kinase activationJ. Biol. Chem.199226723092230981358881 65.BergmannMet al.A genetically engineered" exact="influenza" post="A virus with ras-dependent oncolytic propertiesCancer Res.2001618188819311719449 66.MasemannDet al.Oncolytic"/>
  <result pre="influenza A virus with ras-dependent oncolytic propertiesCancer Res.2001618188819311719449 66.MasemannDet al.Oncolytic" exact="influenza" post="virus infection restores immunocompetence of lung tumor-associated alveolar macrophagesOncoimmunology20187e142317129721377"/>
  <result pre="immunocompetence of lung tumor-associated alveolar macrophagesOncoimmunology20187e142317129721377 67.KasloffSBet al.Oncolytic activity of" exact="avian influenza" post="virus in human pancreatic ductal adenocarcinoma cell linesJ. Virol.2014889321933424899201"/>
  <result pre="of lung tumor-associated alveolar macrophagesOncoimmunology20187e142317129721377 67.KasloffSBet al.Oncolytic activity of avian" exact="influenza" post="virus in human pancreatic ductal adenocarcinoma cell linesJ. Virol.2014889321933424899201"/>
  <result pre="al.Activation of interferon regulatory factor 3 is inhibited by the" exact="influenza" post="A virus NS1 proteinJ. Virol.2000747989799610933707 69.GiglioPet al.PKR and GCN2"/>
  <result pre="in melanoma cellsOncoimmunology20187e146676530221067 70.ObeidMet al.Calreticulin exposure dictates the immunogenicity of" exact="cancer" post="cell deathNat. Med.200713546117187072 71.GeissGKet al.Cellular transcriptional profiling in influenza"/>
  <result pre="of cancer cell deathNat. Med.200713546117187072 71.GeissGKet al.Cellular transcriptional profiling in" exact="influenza" post="A virus-infected lung epithelial cells: the role of the"/>
  <result pre="and 18J. Gen. Virol.20058618519515604446 73.SturlanSet al.Endogenous expression of proteases in" exact="colon cancer" post="cells facilitate influenza A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775"/>
  <result pre="18J. Gen. Virol.20058618519515604446 73.SturlanSet al.Endogenous expression of proteases in colon" exact="cancer" post="cells facilitate influenza A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775"/>
  <result pre="73.SturlanSet al.Endogenous expression of proteases in colon cancer cells facilitate" exact="influenza" post="A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775 74.KuznetsovaIet al.Targeting an"/>
  <result pre="A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775 74.KuznetsovaIet al.Targeting an oncolytic" exact="influenza" post="A virus to tumor tissue by elastaseMol. Ther. Oncolytics20177374429034314"/>
  <result pre="genomic RNA during negative-strand RNA virus infectionCell201014039740820144762 78.HsuMTParvinJDGuptaSKrystalMPalesePGenomic RNAs of" exact="influenza" post="viruses are held in a circular conformation in virions"/>
  <result pre="sequencingProc. Natl Acad. Sci. USA2010107163031630820805493 80.BergmannMMusterTThe relative amount of an" exact="influenza" post="A virus segment present in the viral particle is"/>
  <result pre="5’-phosphatesScience2006314997100117038589 82.RomanovaJet al.Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1" exact="influenza" post="vaccinePLoS One20094e598419543385 83.WacheckVet al.A novel type of influenza vaccine:"/>
  <result pre="DeltaNS1 H5N1 influenza vaccinePLoS One20094e598419543385 83.WacheckVet al.A novel type of" exact="influenza" post="vaccine: safety and immunogenicity of replication-deficient influenza virus created"/>
  <result pre="novel type of influenza vaccine: safety and immunogenicity of replication-deficient" exact="influenza" post="virus created by deletion of the interferon antagonist NS1J."/>
  <result pre="Infect. Dis.201020135436220039806 84.NicolodiCet al.Safety and immunogenicity of a replication-deficient H5N1" exact="influenza" post="virus vaccine lacking NS1Vaccine2019373722372931155415 85.SachetMet al.Improvement of a dendritic"/>
  <result pre="85.SachetMet al.Improvement of a dendritic cell-based tumour vaccine by an" exact="influenza" post="virusEur. J. Clin. Invest2009391000100919807781 86.EffersonCLet al.Prostate tumor cells infected"/>
  <result pre="Clin. Invest2009391000100919807781 86.EffersonCLet al.Prostate tumor cells infected with a recombinant" exact="influenza" post="virus expressing a truncated NS1 protein activate cytolytic CD8+"/>
  <result pre="of peripheral blood mononuclear cellsPLoS One20094e412219125202 88.MasicABabiukLAZhouYReverse genetics-generated elastase-dependent swine" exact="influenza" post="viruses are attenuated in pigsJ. Gen. Virol.20099037538519141446 89.StechJGarnHWegmannMWagnerRKlenkH-DA new"/>
  <result pre="attenuated in pigsJ. Gen. Virol.20099037538519141446 89.StechJGarnHWegmannMWagnerRKlenkH-DA new approach to an" exact="influenza" post="live vaccine: modification of the cleavage site of hemagglutininNat."/>
  <result pre="al.Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine" exact="influenza" post="virus vaccine administered intranasally in pigsVaccine2010287098710820708697 91.de GraafJFde VorLFouchierRAMvan"/>
  <result pre="nuclear export protein allows stable transgene expression in a chimaeric" exact="influenza" post="A virus vectorJ. Gen. Virol.20149533734924222196 93.WolschekMet al.Establishment of a"/>
  <result pre="virus vectorJ. Gen. Virol.20149533734924222196 93.WolschekMet al.Establishment of a chimeric, replication-deficient" exact="influenza" post="A virus vector by modulation of splicing efficiencyJ. Virol.2011852469247321177819"/>
  <result pre="virus vector by modulation of splicing efficiencyJ. Virol.2011852469247321177819 94.HockKet al.Oncolytic" exact="influenza" post="A virus expressing interleukin-15 decreases tumor growth in vivoSurgery201716173574627776794"/>
  <result pre="tumor growth in vivoSurgery201716173574627776794 95.PenghuiYet al.Oncolytic activity of a novel" exact="influenza" post="A virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinomaHum."/>
  <result pre="colony-stimulating factor in hepatocellular carcinomaHum. Gene Ther.20193033033830205709 96.HamiltonJRVijayakumarGPalesePA recombinant antibody-expressing" exact="influenza" post="virus delays tumor growth in a mouse modelCell Rep.2018221729298413"/>
  <result pre="lymphocytes (CTLs) by human dendritic cells infected with an attenuated" exact="influenza" post="A virus expressing a CTL epitope derived from the"/>
  <result pre="tumor cells to TLR3-mediated apoptosisCell Death Differ.20132082383323449395 99.WeissRet al.Interleukin-24 inhibits" exact="influenza" post="A virus replication in vitro through induction of toll-like"/>
  <result pre="Cell Biol.20141513514724452471 101.KabiljoJHarpainFCarottaSBergmannMRadiotherapy as a backbone for novel concepts in" exact="cancer" post="immunotherapyCancers (Basel)20191279 102.SnyderAGet al.Intratumoral activation of the necroptotic pathway"/>
  <result pre="antitumor immunitySci. Immunol.20194eaaw200431227597 103.KuriakoseTet al.ZBP1/DAI is an innate sensor of" exact="influenza" post="virus triggering the NLRP3 inflammasome and programmed cell death"/>
  <result pre="of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during" exact="influenza" post="virus infection to promote host survivalCell Host Microbe201415233524439895 105.TeifkeJPet"/>
  <result pre="Microbe201415233524439895 105.TeifkeJPet al.Pathology of natural infections by H5N1 highly pathogenic" exact="avian influenza" post="virus in mute (Cygnus olor) and whooper (Cygnus cygnus)"/>
  <result pre="105.TeifkeJPet al.Pathology of natural infections by H5N1 highly pathogenic avian" exact="influenza" post="virus in mute (Cygnus olor) and whooper (Cygnus cygnus)"/>
  <result pre="increased host immune and cell death responses induced by 1918" exact="influenza" post="virusNature200644357858117006449 107.HuiKPYet al.Highly pathogenic avian influenza H5N1 virus delays"/>
  <result pre="death responses induced by 1918 influenza virusNature200644357858117006449 107.HuiKPYet al.Highly pathogenic" exact="avian influenza" post="H5N1 virus delays apoptotic responses via activation of STAT3Sci."/>
  <result pre="responses induced by 1918 influenza virusNature200644357858117006449 107.HuiKPYet al.Highly pathogenic avian" exact="influenza" post="H5N1 virus delays apoptotic responses via activation of STAT3Sci."/>
  <result pre="delays apoptotic responses via activation of STAT3Sci. Rep.201662859327344974 108.HuiKPYet al.H5N1" exact="influenza" post="virus-induced mediators upregulate RIG-I in uninfected cells by paracrine"/>
  <result pre="in a specific imbalanced inflammatory responseJ. Immunol.201118616417321106851 110.HartmannBMet al.Pandemic H1N1" exact="influenza" post="A viruses suppress immunogenic RIPK3-driven dendritic cell deathNat. Commun.20178193129203926"/>
  <result pre="RIPK3-driven dendritic cell deathNat. Commun.20178193129203926 111.GabaAet al.The NS1 protein of" exact="influenza" post="A virus participates in necroptosis by interacting with MLKL"/>
  <result pre="and membrane translocationJ. Virol.201993e018351830355688 112.GongYet al.The role of necroptosis in" exact="cancer" post="biology and therapyMol. Cancer20191810031122251 113.HolzeCet al.Oxeiptosis, a ROS-induced caspase-independent"/>
  <result pre="apoptosis-like cell-death pathwayNat. Immunol.20181913014029255269 114.OgbomoHet al.Tumor cells infected with oncolytic" exact="influenza" post="A virus prime natural killer cells for lysis of"/>
  <result pre="In VitroPLoS One20149e11201425390891 116.NakashimaHNguyenTChioccaEACombining HDAC inhibitors with oncolytic virotherapy for" exact="cancer" post="therapyOncolytic Viroth20154183191 117.HamanoSet al.Oncolytic reovirus combined with trastuzumab enhances"/>
  <result pre="enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric" exact="cancer" post="cellsCancer Lett.201535684685425444894 118.LaengleJet al.Histone deacetylase inhibitors valproic acid and"/>
  <result pre="to the same extent in both adjuvant and metastatic HER2/neu" exact="breast cancer" post="patientsJ. Transl. Med.20131130724330813 120.JhawarSRet al.Radiation therapy and talimogene laherparepvec"/>
  <result pre="the same extent in both adjuvant and metastatic HER2/neu breast" exact="cancer" post="patientsJ. Transl. Med.20131130724330813 120.JhawarSRet al.Radiation therapy and talimogene laherparepvec"/>
 </snippets>
</snippetsTree>
